GlassScriptPhysician profile
Melchor Sipalay
NPI 1356390074
$4,319.58
in general payments reported to CMS, 2019-2025
46 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $690 · 2021: $826 · 2022: $694 · 2023: $652 · 2024: $632 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $631.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $561.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $411.03 | 2019-2025 | |
| Lilly USA, LLC | $276.67 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $253.45 | 2019-2021 | |
| Abbvie INC. | $238.32 | 2020-2024 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $220.98 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $188.88 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.73 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $113.99 | 2020-2024 | |
| Glaxosmithkline, LLC. | $103.08 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $88.98 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $83.96 | 2023-2025 | Veozah |
| Aimmune Therapeutics, INC. | $81.44 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $72.44 | 2023-2025 | Cologuard Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melchor Sipalay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.